Riding the integrin wave in thrombosis

The use of platelet integrin a_2bb₃ inhibitors in thrombosis, while clinically very effective, is associated with a high risk of bleeding that has limited their use. Now, researchers at the University of Illinois at Chicago have applied their new insights into the integrin-signaling mechanism to develop an integrin a_2bb₃ inhibitor that suppresses arterial thrombosis without triggering bleeding in mice.¹

Next, the team will assess the inhibitor's therapeutic efficacy, toxicity and pharmacological profiles in animal models of thrombosis...